Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
The two randomisation groups had similar serum 25(OH)D at randomisation (Table 1), but serum 25(OH)D was higher in the women randomised to cholecalciferol at 34 weeks’ gestation (placebo: 41.4 (SD 20.7) nmol/l; cholecalciferol 66.2 (SD 20.3) nmol/l, p < 0.001) as an anticipated consequence of the trial intervention.Baseline characteristics of women randomised to placebo or 1000 IU/day cholecalciferol at 14 to 17 weeks’ gestation until deliveryPlacebo (n = 368)Cholecalciferol (n = 366)nnAge at delivery (years), mean (SD)36831.2 (5.1)36631.1 (5.1)White ethnicity, n (%)367349 (95.1%)363347 (95.6%)Nulliparous, n (%)364154 (42.3%)365156 (42.7%)Height (cm), mean (SD)364166.0 (6.7)365165.5 (6.2)Weight (kg), mean (SD)36873.3 (14.2)36670.9 (14.1)BMI (kg/m2), mean (SD)36426.6 (5.0)36525.9 (4.9)Smoking in early pregnancy, n (%)36632 (8.7%)36528 (7.7%)Moderate/strenuous physical activity (hours/week), mean (SD)2840.95 (0.81)2870.89 (0.66)Educated to A level or more, n (%)363271 (74.7%)364280 (76.9%)Pre-existing hypertension, n (%)3684 (1.1%)3663 (0.8%)Systolic BP at booking (mmHg), mean (SD)310110 (11)305109 (10)Diastolic BP at booking (mmHg), mean (SD)31166 (9)30566 (8)25(OH)D at randomisation (nmol/l), mean (SD)36044.4 (16.4)35745.6 (16.4)
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Randomised controlled trial.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Meta-analysis unclear · Double-blind reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
The effect of pregnancy vitamin D supplementation on maternal blood pressure: real-world data analysis within the MAVIDOS randomised placebo-controlled trial
Source: Article title.
MAVIDOS was a multi-centre double-blind randomised placebo-controlled trial of vitamin D supplementation in pregnancy.
Source: Methods.
In brief, women aged > 18 years with a singleton pregnancy attending one of three research centres in the United Kingdom (University Hospital Southampton NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust and Sheffield Hospitals NHS Trust) between 11 and 14 weeks’ gestation for dating scanning between 10th October 2008 and 11th February 2014 were invited to participate in the study.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
The effect of pregnancy vitamin D supplementation on maternal blood pressure: real-world data analysis within the MAVIDOS randomised placebo-controlled trial
Randomised controlled trial · Archives of Gynecology and Obstetrics · 2025
Original publication title
The effect of pregnancy vitamin D supplementation on maternal blood pressure: real-world data analysis within the MAVIDOS randomised placebo-controlled trial
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Observational studies have suggested negative associations between maternal 25-hydroxyvitamin D (25(OH)D) status and risk of hypertensive disorders of pregnancy [pregnancy-induced hypertension (PIH) and preeclampsia (PET)]. Data from intervention studies are limited. We hypothesised that vitamin D supplementation would lower maternal blood pressure (BP) during pregnancy and reduce the incidence of hypertensive disorders of pregnancy.
Source: PurposeAbstract: What methods does the paper describe?
The Maternal Vitamin D Osteoporosis Study (MAVIDOS) was a randomised placebo-controlled trial. Pregnant women with a baseline 25(OH)D of 25 to 100 nmol/l were randomized to either 1000 IU/day cholecalciferol or placebo from 14 to 17 weeks’ gestation until delivery. BP recordings documented during routine clinical pregnancy care were obtained from clinical records and grouped into gestational windows based on the schedule for routine antenatal care in the United Kingdom (23+0: 24+6, 27+0: 28+6, 33+0: 35+6, 37+0: 38+6, 39+0: 40+6 and ≥ 41+0 weeks+days).
Systolic and diastolic BP measurements in these gestational windows were compared between randomisation groups. Diagnoses of PIH or PET (in accordance with national guidelines) and the use of antihypertensive agents were also noted and compared between groups.
Source: MethodsAbstract: Results
Data for 734 women (366 cholecalciferol, 368 placebo) were included. Maternal mean systolic and diastolic BP did not differ between the randomization groups at any of the gestations studied. The incidences of PIH (placebo 1.6%, cholecalciferol 3.6%, p = 0.10) and PET (placebo 3.3%, cholecalciferol 3.8%, p = 0.68) were similar between the two groups.
Source: ResultsAbstract: Conclusions
Gestational vitamin D supplementation with 1000 IU/day from 14 to 17 weeks gestation did not lower maternal BP or reduce the incidences of PIH or PET in this trial.
Source: ConclusionsAuthors’ abstract
Purpose
Observational studies have suggested negative associations between maternal 25-hydroxyvitamin D (25(OH)D) status and risk of hypertensive disorders of pregnancy [pregnancy-induced hypertension (PIH) and preeclampsia (PET)]. Data from intervention studies are limited. We hypothesised that vitamin D supplementation would lower maternal blood pressure (BP) during pregnancy and reduce the incidence of hypertensive disorders of pregnancy.
Methods
The Maternal Vitamin D Osteoporosis Study (MAVIDOS) was a randomised placebo-controlled trial. Pregnant women with a baseline 25(OH)D of 25 to 100 nmol/l were randomized to either 1000 IU/day cholecalciferol or placebo from 14 to 17 weeks’ gestation until delivery. BP recordings documented during routine clinical pregnancy care were obtained from clinical records and grouped into gestational windows based on the schedule for routine antenatal care in the United Kingdom (23+0: 24+6, 27+0: 28+6, 33+0: 35+6, 37+0: 38+6, 39+0: 40+6 and ≥ 41+0 weeks+days).
Systolic and diastolic BP measurements in these gestational windows were compared between randomisation groups. Diagnoses of PIH or PET (in accordance with national guidelines) and the use of antihypertensive agents were also noted and compared between groups.
Results
Data for 734 women (366 cholecalciferol, 368 placebo) were included. Maternal mean systolic and diastolic BP did not differ between the randomization groups at any of the gestations studied. The incidences of PIH (placebo 1.6%, cholecalciferol 3.6%, p = 0.10) and PET (placebo 3.3%, cholecalciferol 3.8%, p = 0.68) were similar between the two groups.
Conclusions
Gestational vitamin D supplementation with 1000 IU/day from 14 to 17 weeks gestation did not lower maternal BP or reduce the incidences of PIH or PET in this trial.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00404-025-07958-z.
Publication and source details
Original title: The effect of pregnancy vitamin D supplementation on maternal blood pressure: real-world data analysis within the MAVIDOS randomised placebo-controlled trial
Natasha L. Citeroni-Clark; Stefania D’Angelo; Sarah R. Crozier; Alexandra Kermack; Keith M. Godfrey; Cyrus Cooper; Nicholas C. Harvey; Rebecca J. Moon
Archives of Gynecology and Obstetrics · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100012041Versus Arthritis17702Cooper Cyrus http://dx.doi.org/10.13039/501100000265Medical Research CouncilMC_PC_21003MC_PC_21001Cooper Cyrus http://dx.doi.org/10.13039/501100000355Bupa Foundationhttp://dx.doi.org/10.13039/501100022419National Institute for Health Research Southampton Biomedical Research Centrehttp://dx.doi.org/10.13039/501100000272National Institute for Health and Care ResearchNF-SI-0515-10042Godfrey Keith M. http://dx.doi.org/10.13039/501100002283Alzheimer’s Research UKARUK-PG2022A-008Godfrey Keith M. http://dx.doi.org/10.13039/100010661Horizon 2020 Framework Programme289346613977Harvey Nicholas C.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T02:29:38.578762+00:00
DOI: 10.1007/s00404-025-07958-z · PMC11985589